Navigation Links
$1.8 million grant supports investigation of psoriasis link to cardiovascular disease
Date:9/20/2012

Armed with a new $1.8 million grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, dermatology researcher Nicole Ward, PhD, assistant professor of dermatology and neurosciences at Case Western Reserve School of Medicine, will lead a study examining the link between psoriasis and heart attack and stroke.

The work will advance research conducted earlier this year in Dr. Ward's lab. She and colleagues at the University Hospitals Harrington Heart & Vascular Institute, published a major discovery that psoriasis could cause the development of cardiovascular disease in mouse models. The team of researchers also found that aggressive treatment of the skin disease reversed the cardiovascular disease.

"Prior to our recent publication, the evidence linking these two diseases was entirely at the epidemiological level and didn't show mechanistic insight for why this occurred," says Dr. Ward, who is also a scientist with the Murdough Family Center for Psoriasis at University Hospitals Case Medical Center. "Our goal was to examine whether psoriasis influences cardiovascular disease. Psoriasis was previously thought of as a disease that severely affected skin appearance as well as the patient's quality of life. We now know it decreases a patient's life span by seven years."

Dr. Ward and colleagues will work to identify intrinsic changes in the skin cells and the subsequent cascade of events that leads to blood-clot formation in either heart attack or stroke. By identifying this trigger, the researchers hope to provide first-ever evidence that cell-specific events in psoriasis can be targeted for treatment.

This preclinical evidence will impact the approach to patient clinical care, as doctors will need to be more aggressive in monitoring for cardiovascular disease and other co-morbidities in those with moderate to severe-plaque psoriasis. By treating and keeping the skin disease in check, the risk for heart-related inflammation is reduced as well. In addition, they will conduct preclinical testing of the efficacy of current psoriasis medication on cardiovascular disease.

"Dr. Ward's research discovery is quite exciting," says Kevin Cooper, MD, professor and chair of the Department of Dermatology at Case Western Reserve School of Medicine and University Hospitals Case Medical Center, "It demonstrates for the first time that a mouse model of psoriasis exhibits a cardiovascular co-morbidity often seen in human psoriasis patients. Importantly, the basis of Dr. Ward's grant demonstrates that aggressively treating the skin disease improved the cardiovascular complications associated with psoriasis. The work supported by this grant will help to pinpoint how current therapeutics for psoriasis may also improve co-morbidities associated with chronic skin inflammation."


'/>"/>

Contact: Jessica Studeny
jessica.studeny@case.edu
216-368-4692
Case Western Reserve University
Source:Eurekalert

Related medicine news :

1. Systems biologist receives $2.5 million Pioneer Award for genome research
2. Scripps Research Institute receives $20 million to shed light on HIV drug resistance
3. FEMA awards $1 Million to WPI to develop groundbreaking toxic gas sensors for firefighters
4. IU optometrist receives $1.9 million to assess street-crossing program
5. Moffitt Cancer Center researcher receives $2.1 million grant from NCI for answering Provocative Question
6. Scientist receives $2.8 Million to study cell signaling mechanism and develop potential therapeutics
7. Nearly $50 million in research funding awarded by NSF
8. $8.9 million NIH grant to study genomic link to premature heart disease
9. UCF nanoscientist receives $2 million NIH award
10. Saving brains in developing countries: $11.8 million for innovative ideas worldwide
11. Funding for neglected global diseases research at UBC exceeds $20 million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
(Date:10/12/2017)... ... 12, 2017 , ... Vohra Chief Medical Officer Dr. Shark ... skilled nursing facility medical directors and other clinicians at various events in October. ... "At many of these conferences we get to educate other physicians, facility nurses, ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology: